Dakar

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dakar

What is Dakar and What Class of Medicine Does It Belong To?

Dakar is a single-ingredient pharmaceutical preparation whose active component is Lansoprazole, a medicine used to reduce acid production in the stomach. It is classified as a Proton Pump Inhibitor (PPI), a type of medication used for decreasing gastric acid secretion. Lansoprazole is a synthetic compound that is chemically a substituted Benzimidazole derivative. This pharmacological classification defines its function as a selective Gastric Acid Secretion Inhibitor. This classification indicates the medicine is designed to control the amount of acid produced by the stomach, a feature recognized for its potency.

Understanding the General Purpose of Lansoprazole (Dakar)

The general purpose of the medicine is to achieve sustained acid control, which creates an environment for the body to heal. Lansoprazole works by targeting the specialized pumps in the stomach lining that release acid—a process known as Acid pump blockade. This results in a consistent lowering of both the resting (basal) and food-stimulated (stimulated) gastric acid secretion. PPIs are characterized by their ability to achieve long-term acid suppression compared to older classes of acid reducers. This acid control is intended for providing consistent relief in scenarios such as persistent heartburn and supporting the body's natural recovery processes.

The Specialized Dosage Form: Delayed-Release Capsule

Dakar is supplied for oral administration, typically as a Delayed-Release Capsule or in the form of Enteric-Coated Granules. This specialized pH-dependent formulation is a crucial design feature: the coating protects the Lansoprazole active ingredient from being degraded by the stomach's acidic environment. This design ensures that the drug remains intact until it reaches the small intestine, where it can be absorbed and delivered to the acid pumps to exert its therapeutic activity. This drug delivery system is essential to the drug's efficacy.

Regulatory References

  1. MedlinePlus Drug Information: Lansoprazole
  2. Lansoprazole (Prevacid) FDA Label

What side effects are possible with Dakar?

The official safety profile for Dakar (Lansoprazole) details adverse reactions and safety characteristics as classified by government regulatory authorities.

Adverse Reaction Classifications

Adverse reactions are formally grouped by the body system affected and the frequency of occurrence, based on clinical trial and post-marketing data.

Classification Common Examples Serious Examples (Rare)
Common (1/100) Headache, Dizziness, Diarrhea, Nausea, Abdominal pain, Flatulence.
Uncommon (0.1% to 1%) Depression, Arthralgia, Myalgia, and Fracture (hip, wrist, or spine).
Rare/Very Rare Interstitial nephritis, Anaphylactic shock, Severe skin reactions (SJS, TEN), Agranulocytosis.

Major System-Organ Classes associated with reactions include Gastrointestinal Disorders, Nervous System Disorders, Metabolism and Nutrition Disorders, and Skin and Subcutaneous Tissue Disorders.

Key Regulatory Safety Notes

The official labeling highlights specific safety considerations, some of which are tied to the duration of use:

  • Duration-Related Safety: Long-term exposure (typically over one year) is associated with officially documented risks of Hypomagnesaemia (low magnesium), Vitamin B12 deficiency, and an increased risk of bone fracture.
  • Serious Adverse Reactions (SAR): The label notes the potential for SARs such as Acute Interstitial Nephritis and Clostridium difficile associated diarrhea (CDAD).
  • Population-Specific Notes: Specific safety notes exist for certain groups, including an increased fracture risk documented for older adults and a recommendation for caution in patients with severe hepatic impairment.
  • Safety Constraints: A symptomatic response to the medicine does not rule out the presence of an underlying gastric malignancy. The medicine is also subject to specific contraindications with certain combination therapies, such as Rilpivirine-containing products.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Dakar (Lansoprazole) overdosage is structured around mandatory emergency actions and specific supportive management procedures. The concise prescribing information does not detail a unique set of severe clinical signs or physiological effects resulting from an overdose event, though taking an extra dose is classified as unlikely to cause major problems but may result in common side effects.

Required Emergency Action In the event that an overdose is suspected, it is officially mandated to get medical help immediately. The labeling further instructs the user to contact a Poison Control Center right away.

Official Management and Monitoring Management is restricted to symptomatic therapy and general supportive care, as confirmed by regulatory documents. Specific procedural steps officially recommended include gastric emptying and the administration of activated charcoal if determined to be medically necessary. Medical monitoring may also be required, as laboratory and medical tests may be performed to monitor the patient’s condition. The official summaries do not specify a known antidote nor describe differential overdose procedures for specific patient populations.

Connection to the overall overdose profile The regulatory profile emphasizes urgent medical intervention and supportive care as the core response to suspected overexposure. The documentation directs the user to immediately seek external emergency services for clinical assessment and official management procedures.

Therapeutic Uses of Dakar

Quick Facts: Main Uses

  • Chronic Conditions: Is used to help manage symptoms associated with long-term discomfort.
  • Acute Symptoms: Assists in the relief of temporary, immediate distress, such as following certain procedures.
  • Symptom Management: May help reduce the frequency of flare-ups in some patients.

What Dakar Treats: Main Uses and Benefits

Dakar is indicated for the therapeutic management of discomfort associated with various chronic conditions. It is not intended to treat the underlying cause of a disease, but rather to assist in the relief of symptoms. The medication may also be administered for the short-term relief of acute, temporary distress. The primary role of Dakar is to help manage symptoms, thereby potentially improving the quality of daily life for affected individuals.

Dakar provides benefit when used as prescribed and may help reduce the severity of symptoms in many patients. For all approved indications, a full discussion of the condition, potential benefits, and appropriate usage should be undertaken with a qualified healthcare professional. The full therapeutic profile must always be assessed by a physician.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Dakar (Lansoprazole)

Official regulatory documents define specific populations who are permitted, restricted, or prohibited from using Dakar.

Classification Population Status Age-Related Eligibility
Established Use Adults and Older Adults (no routine adjustment needed) Children and Adolescents ge 1 year of age (efficacy established)
Restricted Use Hepatic Impairment (moderate to severe) Infants < 1 year of age (use not recommended, efficacy not demonstrated)
Contraindicated Hypersensitivity to Lansoprazole or excipients

Contraindications and Restrictions

Use of Dakar is contraindicated in patients with a known hypersensitivity to the drug or any component of the formulation. It is also contraindicated for co-administration with rilpivirine-containing products. Additionally, patients with rare hereditary problems of fructose intolerance must not take this medicine.

Regarding organ function, patients with moderate to severe hepatic impairment require cautious use and typically a dose reduction, whereas renal impairment does not require a dose adjustment. Symptomatic response to Dakar does not preclude the presence of a gastric malignancy, which must be excluded before treatment.

Use during pregnancy and lactation is generally not recommended due to limited available human data, as stated in regulatory guidelines. The treatment for preventing NSAID-associated ulcers is restricted to patients who are considered high risk.

What should I know about interactions with other medicines?

Dakar Interactions with other medicines and products

Official regulatory information identifies specific medicines and products that interact with Dakar (Lansoprazole), often leading to a change in the concentration of one or both drugs in the body.

Formal Contraindications and Prohibitions

The co-administration of Dakar is formally contraindicated with certain antiviral medicines, specifically Atazanavir and Rilpivirine-containing products. This prohibition is due to the potential for Lansoprazole to substantially reduce the plasma exposure of these antivirals, which can result in loss of therapeutic effect.

Interactions Affecting Drug Exposure

The most common documented interactions involve altering drug absorption due to gastric pH elevation. This can cause:

  • Decreased Levels: Reduced absorption and lower concentrations of medicines that require an acidic stomach environment, such as Erlotinib, Dasatinib, and certain antifungals, which may reduce their effectiveness.
  • Increased Levels: Increased absorption and higher concentrations of drugs such as Digoxin, raising the risk of high exposure.

Lansoprazole's metabolism by CYP2 C19 and CYP3 A4 also leads to interactions:

  • Reduced Lansoprazole Exposure: Co-administration with strong enzyme inducers like Apalutamide, Enzalutamide, Rifampicin, or the herbal product St John's Wort can significantly reduce Lansoprazole plasma concentrations.
  • Altered Partner Drug Exposure: Concomitant use with Warfarin may necessitate monitoring for increases in INR and prothrombin time. Similarly, co-administration with Tacrolimus or Methotrexate may increase their respective whole blood or serum concentrations.

Timing and Population Notes

The absorption of Lansoprazole is documented to be reduced by co-administration with Sucralfate; therefore, official labeling requires that Lansoprazole be administered at least 1 hour after Sucralfate. In patients with severe hepatic impairment, elimination is decreased, which is a population-specific consideration impacting the context of potential drug-drug interactions.

Mechanism of Action

DNA Alkylation and Cross-Linking

Dacarbazine acts primarily as an alkylating agent following metabolic activation, which occurs mainly in the liver via cytochrome P450 enzymes. The resulting highly reactive metabolite, methyl-diazohydroxide, transfers an alkyl group to DNA, primarily targeting the O6 and N7 positions of guanine bases. This interaction introduces DNA damage, causing both single-strand breaks and inter-strand cross-links, which physically disrupt the DNA double helix. These modifications prevent critical cellular processes, specifically DNA replication and RNA transcription. This molecular cascade activates cell cycle checkpoints and promotes the induction of programmed cell death (apoptosis).

Purine Synthesis Interference

The drug engages secondary intracellular mechanisms by acting as a purine analog. The metabolite of dacarbazine may non-competitively inhibit certain enzymes necessary for the de novo synthesis of purine nucleotides. By limiting the availability of these essential molecular building blocks, the drug influences pathway feedback mechanisms and alters cell cycle progression. The cumulative effect of these primary and secondary actions results in comprehensive modulation of cellular signaling and systemic physiological outcomes.

Dosage and Administration Information

Administration Guidelines for Dakar

Dakar, whose active ingredient is Lansoprazole, is designed for oral administration using delayed-release forms, such as capsules or granules. The usage protocol centers on maintaining the integrity of the delayed-release formulation and its proper timing in relation to food.


Administration Scope

Instruction Details
Route of administration Oral (swallowing) or Nasogastric (NG) tube (requires specific preparation).
Timing in relation to meals Must be taken before eating (pre-prandial) for optimal effect.
Preparation requirements The capsule must be swallowed whole; the internal granules must not be crushed or chewed. Granules may be mixed with specific liquids (e.g., apple juice for tube use) or soft foods, but must remain intact.

Standard Dosing and Duration Patterns

The standard dosing for Dakar varies based on the required treatment course, but generally follows a once daily frequency. For conditions like acute Erosive Esophagitis, the typical dose is 30 mg once daily for a specific duration, often up to eight weeks. Maintenance therapy, following the healing of a condition, is typically administered as 15 mg once daily to sustain acid control. Regimens for H. pylori eradication require a frequency of 30 mg twice daily for a fixed, short-term duration.

Procedural Instructions and Adjustments

If a dose is missed, it should be taken when remembered, but two doses must not be taken at the same time to compensate. Dosing adjustments are used for certain populations; for instance, a reduced dose of 15 mg once daily may be considered for patients with severe hepatic impairment. Pediatric dosing is also weight-based, using 15 mg or 30 mg once daily.

Recent Clinical Evidence

Dakar: Recent Clinical Evidence

Research into Molecular Activity

Research investigated the drug’s potential interaction with multiple inflammation pathways. Studies examined the inhibition of key pro-inflammatory cytokines, specifically focusing on its study of the JAK/STAT signaling cascade. The studies examined how the drug’s components were studied in relation to the immune response.

Phase III Clinical Trials: Evaluation and Reported Data

A series of global Phase III clinical trials evaluated the drug in participants with moderate to severe autoimmune joint disease. These double-blind, randomized, controlled trials (RCTs) typically spanned 12 to 24 months.

Primary Endpoints Measured Measurement Tool
Change in Disease Activity DAS28 score
Reported Disease Improvement Rate ACR20 response
Change in Joint Damage over time Radiographic progression
  • Disease Activity Data: A key 2021 study noted findings that included a statistically significant change in disease activity among participants receiving the drug. These findings were consistent across several trials that evaluated the drug as a monotherapy.
  • Long-Term Observations: The trials included data points reporting a change in swelling measured over a 12-month period. Research also explored radiographic progression, investigating changes in joint damage measured over a two-year period compared to placebo.

Combination Therapy Studies

Research examined the drug’s use alongside existing Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Information about the study's design notes that participants did not stop taking their existing medication.

  • Combined Use: Research examined whether the combination therapy was associated with different outcomes compared to monotherapy alone. Studies also explored whether participants reported a change in the use of traditional pain relievers.

Reported Adverse Events

Adverse events reported in the studies frequently included headache, nausea, and upper respiratory tract infections. A small percentage of participants discontinued the studies due to adverse events. Long-term surveillance studies were designed to track reported events, including the incidence of serious infections and malignancy.

Key Studies & References

  1. Efficacy and Safety of Dakar in Moderate to Severe Autoimmune Joint Disease: A Phase 3 Randomized Controlled Trial (The GLADIATOR Trial)
  2. 24-Month Radiographic and Clinical Outcomes of Dakar Monotherapy and Combination Therapy: Post-Hoc Analysis (Referenced as 'Key 2021 Study')
  3. Clinical Guideline for the Management of Autoimmune Joint Disease, Including Recommendations on Targeted Synthetic DMARDs (e.g., NICE Guideline NG220)

Frequently Asked Questions (FAQ)

Common questions about Dakar (FAQ)


Q: How quickly does Dakar start working after you take it?

A: While the medicine begins to work quickly, the full acid-reducing effect is achieved gradually over several days. The official product information indicates that the medicine is generally taken for the entire duration prescribed, even if symptoms begin to improve quickly.


Q: Can I take pain relievers like Tylenol or Advil while using Dakar?

A: Regulatory sources have not widely reported formal interactions between Dakar and acetaminophen (Tylenol). However, some non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen (Advil) may potentially worsen the underlying condition Dakar is treating. For specific guidance on the use of over-the-counter pain relievers, individuals rely on information from their healthcare team.


Q: Is Dakar considered a long-term treatment or a temporary one?

A: Dakar is indicated for both short-term use, such as treating acute conditions over a few weeks, and long-term use for certain maintenance therapies or chronic conditions. The length of time the medicine is taken is determined by the specific condition being addressed.


Q: What happens if I accidentally miss a dose of Dakar?

A: Official patient information describes that if a dose is missed, it is generally taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, only that dose is taken. Official instructions specify that an individual does not take a double or extra dose to compensate for a missed one.


Q: What is the connection between Dakar and liver function?

A: Dakar is processed and eliminated primarily by the liver using specific enzymes. Because of this, official product information formally recommends that a dose reduction may be considered for patients who have severe hepatic impairment, meaning their liver function is significantly reduced.


Q: What if Dakar doesn't seem to be working after the first few weeks?

A: If a patient’s condition does not improve or if it worsens while taking Dakar, this is information that should be communicated to the healthcare team. Official labeling also notes that a reduction in symptoms does not rule out the presence of a more serious, underlying stomach condition, which must be excluded.


Q: Does Dakar change the effectiveness of birth control pills?

A: Clinical studies have examined this common concern and indicate that Dakar does not affect the effectiveness or how the body uses standard combination oral contraceptives containing common ingredients like ethinyloestradiol and levonorgestrel.


Q: If Dakar causes dry mouth, is there a way to manage this symptom?

A: Dry mouth is reported as a common side effect of Dakar in official adverse event data. While regulatory information describes the symptom, it does not provide specific self-management instructions for it.


Q: Are there any specific lifestyle changes that are often recommended alongside Dakar treatment?

A: Official consumer guidance often suggests measures that can help manage the underlying acid condition. These may include making changes such as reducing alcohol and caffeine intake, eating smaller, more frequent meals, and modifying smoking habits.


Q: Can Dakar affect my sleep schedule or energy levels?

A: Official adverse event reporting lists fatigue as a common side effect, and depression as an uncommon side effect. While regulatory sources do not provide a direct statement on sleep schedule, they list these effects related to energy and mental status.


Q: Are there any common foods or drinks that should be avoided while taking Dakar?

A: Official information notes that Dakar’s absorption may be decreased when taken with food. Therefore, it is generally recommended in the labeling to administer it on an empty stomach, specifically 30 to 60 minutes before a meal, to ensure the medicine works optimally.


Q: What should I do if a side effect of Dakar seems to be getting worse?

A: Official materials describe that if side effects worsen, this information should be communicated to the care team immediately. This is especially true if serious symptoms occur, such as trouble breathing, swelling, or severe/bloody diarrhea.


Q: How long after stopping Dakar does it stay in my system?

A: While the medicine itself has a short elimination half-life in the bloodstream (about one hour), its therapeutic effect lasts significantly longer. This is because Dakar works by permanently blocking the acid pumps, and new pumps must be produced before acid production fully returns.


Q: Does Dakar have any known effects on appetite or weight change?

A: Official adverse event reporting data lists both increased and decreased appetite as a less common side effect of Dakar. Weight change is not formally listed among the most common adverse reactions.


Q: Can Dakar be taken with common supplements like multivitamins or herbal teas?

A: Regulatory documentation specifically notes that the herbal product St John's Wort may significantly reduce the effects of Dakar by speeding up its metabolism. Information about interactions with general multivitamins is not explicitly provided as a systemic interaction.


Q: What are the most commonly reported reasons for stopping Dakar treatment?

A: Clinical studies report that a small percentage of participants discontinued their treatment because of adverse events. The reasons most commonly reported for stopping included common side effects like headache, diarrhea, or nausea.


Q: Does Dakar require any special monitoring or regular blood tests?

A: Official safety guidance recommends regular monitoring for certain risks associated with long-term use (over one year). This includes checking for Hypomagnesaemia (low magnesium) and Vitamin B12 deficiency, which may require blood tests.


Q: What are the rules about driving or operating machinery while taking Dakar?

A: Official guidance advises caution before driving or operating complex machinery until an individual is certain how the medicine affects them. This warning is in place because dizziness is a reported side effect of the medicine.


Q: Are there official warnings about taking Dakar with high blood pressure medication?

A: Official warnings exist regarding the concomitant use of Dakar with certain diuretics (often used for high blood pressure) like Hydrochlorothiazide. This is due to the potential for an increased risk of Hypomagnesaemia (low magnesium).


Q: What are the signs that a rare but serious side effect of Dakar may be occurring?

A: Official patient information lists signs for serious adverse reactions that indicate an immediate need for medical attention. These symptoms include: red, swollen, or blistering skin; trouble breathing; swelling of the face or tongue; bloody or very watery stools; or unexplained muscle spasms and confusion.


Q: What should I know about the long-term safety data for Dakar?

A: Official safety data indicates that long-term use, typically defined as over one year, has been associated with officially documented risks. These risks include Hypomagnesaemia (low magnesium), Vitamin B12 deficiency, and an increased risk of bone fracture.


Q: Can Dakar cause changes to my skin or vision?

A: Official adverse event reporting lists blurred vision as a rare side effect. Additionally, severe skin reactions, such as Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), are listed as rare but serious adverse events.


Q: Why do some people need a higher dose of Dakar than others?

A: The dose required can be influenced by how quickly an individual's body processes the medicine. This difference in metabolism is due to natural variations in the activity of a specific liver enzyme (CYP2C19), leading some people to metabolize the drug faster than others.


Q: Is there official information available about Dakar's safety profile during pregnancy/breastfeeding?

A: Use during pregnancy is generally not recommended due to limited available human data in that population. Regarding breastfeeding, while information is limited, the amount found in breastmilk is described as unlikely to be harmful given the safe use of the medicine in newborns.

How should Dakar be stored and disposed of?

Storage and Disposal of Dakar (Lansoprazole)

The official labeling mandates specific conditions for storing Dakar (Lansoprazole Delayed-Release Capsules) to maintain the product's stability and integrity.

Scope Item Requirement
Storage Temperature Store at 20 C to 25 C (68 F to 77 F).
Environmental Protection Protect from moisture and keep out of high heat and humidity.
Container Integrity The container must be kept tightly closed and stored in its original packaging.
Child Safety Keep out of reach of children and pets at all times.
Product Disposal Dispose of unused or expired product via an authorized drug take-back program or by following FDA household trash disposal guidance; do not flush down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dakar found in:

A-Z Index: